Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

UCB Gets EU Approval For Bimekizumab In Psoriasis

Author: Vandana Singh | August 25, 2021 03:18pm

The European Commission has cleared UCB's (OTC:UCBJF) Bimzelx (bimekizumab) for moderate to severe plaque psoriasis in adults.
UCB's confidence lies in head-to-head studies that pitted Bimzelx against Novartis AG's (NYSE:NVS) Cosentyx (secukinumab) and found that it was better at achieving complete clearance of skin lesions at both 16 and 48 weeks.
Bimekizumab is approved at a recommended dose of 320 mg, administered by two subcutaneous injections every four weeks to week 16 and every eight weeks after that.
Bimzelx has already been pre-approved for NHS reimbursement by NICE. Its costs are likely "similar or lower" than Cosentyx and other biologics used for psoriasis.
Related content: Benzinga's Full FDA Calendar
Price Action: UCBJF shares are up 9.07% at $114.95 during the market session on the last check Wednesday.

Posted In: NVS UCBJF UCBJY